pioglitazone has been researched along with Myelodysplastic Syndromes in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adachi, M | 1 |
| Mitsuhashi, K | 1 |
| Matsuda, H | 1 |
| Watanabe, J | 1 |
| Nakanishi, K | 1 |
1 other study available for pioglitazone and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Myelodysplastic syndrome diagnosed on the occasion of Fournier's gangrene.
Topics: Aged; Anti-Bacterial Agents; Fournier Gangrene; Humans; Male; Myelodysplastic Syndromes; Pioglitazon | 2017 |